Broomfield, CO —  October 18, 2012

Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Ziyad M. Hijazi will present an update on Colibri’s investigational transcatheter aortic valve implantation (TAVI) program at the Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium taking place in Miami Beach, FL from October 22 – 26, 2012. Colibri has developed the world’s first and only pre-mounted, pre-crimped, and pre-packaged low profile, 14 French, TAVI system.

Joseph B. Horn, Colibri’s president and chief executive officer states, “It is an honor to have Dr. Hijazi, an expert in interventional cardiology and a member of our Advisory Board, present an update on Colibri’s strengthened scientific and preclinical evidence to the world’s leaders in interventional cardiovascular medicine at TCT. This is an exciting time for Colibri as we are actively screening patients for inclusion into our first-in-human clinical study at multiple sites outside of the United States.”

Dr. Hijazi will present a scientific and preclinical update on Colibri’s TAVI system as part of the panel “Next Generation Transcatheter Aortic Valve Therapies” scheduled for Wednesday, October 24, 2012 from 2:00 p.m. – 6:15 p.m. ET in room A204-205. In addition, Colibri will be hosting a booth (#1108) where attendees can meet members of Colibri’s management team and learn more about Colibri’s technology.

About Colibri Heart Valve, LLC and the Colibri TAVI System

Colibri Heart Valve, LLC is a privately held medical device company based in Broomfield, CO that researches and develops novel heart valve technologies. Colibri has developed a pre-mounted, pre-crimped, and pre-packaged, ready-for-use transcatheter aortic valve implantation (TAVI) device called the “Colibri TAVI System.” TAVI is an important treatment option for heart valve replacement due to its minimally invasive nature, clinical efficacy, extensive patient experience, and reduced procedural costs. Colibri’s advanced technology is a culmination of over 10 years of research and development by Colibri’s founders, Dr. David Paniagua and Dr. R. David Fish into the tissue, valve design, frame, and delivery catheter. The Company’s unique tissue processing method produces extremely strong, durable, and biocompatible tissue. The proprietary tissue enables loading, crimping, and packaging of the Colibri valve at manufacture, making in-procedure valve rinsing and loading at time of use unnecessary. The “Colibri TAVI System” is designed to be shipped ready-for-use.

Colibri’s corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. For more information, visit: www.colibrihv.com.